Skip to main content

Home/ MaRS/ Group items tagged fund

Rss Feed Group items tagged

Miguel Amante

IT company grows with Ontario aid - Simcoe.com - August 18, 2010 - 0 views

  •  
    Barrie-based IT company gShift Labs qualifies for Investment Accelerator Funding.
Cathy Bogaart

OGI Invests in Personalized Medicine for Age-related Macular Degeneration - November 1,... - 0 views

  •  
    The Ontario Genomics Institute has given funding to MaRS life sciences client, ArcticDX. They'll use the money for studies in preparation for a Food and Drug Administration approval for their product. The funding comes through its Pre-Commercialization Business Development Fund (PBDF)
Sarah Hickman

Angel Investors in Groups Achieve Investment Returns In Line with Other Types of Equity... - 0 views

  •  
    The results of the largest study on the financial returns of angel investors in North America were released earlier this week by the Ewing Marion Kauffman Foundation and the Angel Capital Foundation. The study showed that angels affiliated with organized angel groups achieved an average of 27% internal rate of return on their investments. Overall, ".... [these] groups experienced exits that generated 2.6 times their invested capital in 3.5 years from investment to exit. This return compares favorably to that of other private equity investments, including those of early-stage venture capital." In addition to the study's findings on angel investment outcomes, best practices in angel investing were also identified. Areas linked to investment performance were: * due diligence time * industry expertise among investors * active participation by angels in the funded venture * follow-on investing (interestingly, the study found that " ... [i]n ventures where follow-on investments were made, nearly 70 percent of the exits occurred at a loss.")
Sarah Hickman

Creating an Early Stage Series A Pitch « Adventures in Startups & VC - 0 views

  •  
    Series A pitches have a different emphasis than pitches for later rounds. Improve your presentation by reading this blog post from Common Angels (a Boston-based group of 70 private investors and two co-investment funds under management). The powerpoint template is worth adding to any start-up's collection of resources.
  •  
    Series A pitches have a different emphasis than pitches for later rounds. Improve your presentation by reading this blog post from Common Angels (a Boston-based group of 70 private investors and two co-investment funds under management). The powerpoint template is worth adding to any start-up's collection of resources.
Assunta Krehl

McGuinty government supporting start-up technology companies with MaRS: Connecting inve... - 0 views

  •  
    The McGuinty government announced it is funding the creation and expansion of angel investor network to help Ontario's leading-edge start-up companies to grow and succeed.
  •  
    The McGuinty government announced it is funding the creation and expansion of angel investor network to help Ontario's leading-edge start-up companies to grow and succeed. Oct 4, 2006
Assunta Krehl

Golf Town to host third annual charity tournament in Toronto | World Golf News - 0 views

  • McEwen Centre for Regenerative Medicine - home to one of the world's largest concentrations of stem cell researchers - the 2009 Golf Town Invitational will raise funds for its groundbreaking research toward the treatment and cure of diabetes.
  • Based in the heart of Toronto's Discovery District at the MaRS Centre/Toronto Medical Discovery Tower, the McEwen Centre's vision is to be a world-renowned facility for stem cell biology and regenerative medicine. It is home to one of the world's largest concentrations of stem cell researchers, who are working to accelerate the development of more effective treatments for conditions such as heart disease, diabetes, respiratory disease and spinal cord injury.
  • The event is limited to 20 foursomes and more information is available at www.golftown.com/gti.
  • ...1 more annotation...
  • Today, teams of McEwen Investigators are committed to finding a way to recreate the complex metabolic functions of the human pancreas. By harnessing the power of stem cells to repair, regenerate or replace diseased cells, tissues and organs, they are able to challenge conventional approaches to treatment, and bring new hope to the more than 170 million diabetes sufferers worldwide.
  •  
    McEwen Centre for Regenerative Medicine - 2009 Golf Town Invitational benefit will raise funds for its groundbreaking research toward the treatment and cure of diabetes.
Assunta Krehl

Pharmafocus.com - 0 views

  • Canada has always had to fight hard to attract talent and investment
  • MaRS Vital to Toronto's life sciences vision is MaRS (derived from Medical and Related Sciences) a non-profit organisation and business centre located in the heart of the city. Its core function is as a biotech incubator and business park, known as MaRS Discovery District. The venture was first established in 2000 to help foster and accelerate the growth of successful Canadian businesses and, after some uncertain times, it is now gathering momentum. A separate technology transfer office, MaRS Innovation, has also been established that, it is hoped, can be a world beater in its own right (see Turning good ideas into world beaters below). The location of the MaRS building in central Toronto is important, as it is just a stone's throw away from an existing cluster of universities and academic hospitals. MaRS has many links with other research-based organisations, including collaborations with three local universities, 10 academic teaching hospitals and the Ontario Institute for Cancer Research. MaRS occupies the Old Toronto general hospital, where insulin was first discovered by Best and Banting in 1921 and then developed for use in human trials. The 21st Century organisation can build on this heritage in patient-focused discovery and development. Formerly the head of venture capital firm Primaxis, Ilse Treurnicht is chief executive of MaRS Discovery District. She acknowledges the crisis in venture capital funding, and says Canada's sector has always had less access funds through this route than other countries. This is one of the drivers behind the search for a new approach. Treurnicht says the old models of building biotech and life sciences businesses have to be discarded, as they have failed to build companies with critical mass. She says MaRS' new 'Convergence Innovation' strategy of bringing science, capital and business together will pay off.
  • "We call our strategy 'Convergence Innovation' and what we are trying to do is move away from the old linear model of academics struggling in their spare time to build companies or entrepreneurs doing this in a very incremental way."It takes time and it has many risk points along the way. So using this Convergence centre model to create a much more dynamic organisation which can help accelerate good ideas towards the commercialisation." But she says Canada's geography and demographics are always going to be a challenge. "This is a very large country with a small population. If you think in terms of clusters and hub regions, Canada's business hubs are separated geographically, and there is not much in between in terms of people."That means we can't try to be a little United States, because we just won't show up on the radar. We have to take a different approach. We have to think about collaboration as our potential competitive advantage - that means using networks and associations to solve problems and build businesses."So as new opportunities emerge, we can take them to market faster and hopefully with a higher success rate." The centre currently accommodates numerous start up companies, as well as those providing legal and financial services to them. AstraZeneca and GlaxoSmithKline also have offices on site. In all, MaRS provides mentoring for over 200 different companies across Ontario, and runs courses on entrepreneurship and preparing products for market.
  • ...7 more annotations...
  • Transition Therapeutics is one of the companies based at MaRS, and is an example of a biopharmaceutical company that is taking a new approach to the science and business of drug development.
  • Now Toronto's MaRS Innovation (MI) has been launched to try to guide and accelerate these promising ideas out of the wilderness and onto the market. MI is a not-for-profit technology transfer company that will channel all the best ideas to come out of Toronto's renowned academic centres. In the Toronto and Ontario area there were between 14-16 different technology transfer offices in the different institutions, and MaRS Innovation resolved to bring these interests together into a single entity after industry partners told them it was an inefficient way to do business. Bringing together the different institutions under one umbrella organisation has been an arduous task for MaRS, but the reward could be considerable for all parties. MI now oversees probably the largest intellectual property pipeline of its kind, representing about $1 billion in annual research spending. This means MI will be a unified route for all of Toronto's academics and their institutions when they want to develop and commercialise a bright idea. Most importantly, investors from industry who are looking to collaborate will now be able to deal with just organisation and one IP process. MI will cover patentable ideas across a broad range of areas, and not just life sciences - the discovery pipeline in physical sciences, information and communication technology, and green technology ('cleantech') will all be funnelled through MI. MI now represents three universities, 10 academic teaching hospitals and the Ontario Institute for Cancer Research. MaRS Innovation, with support from MaRS and BioDiscovery Toronto, will advance commercialisation through industry partnerships, licensing and company creation.
  • MI has just announced its first two commercialisation deals with academic partners in the city. The first is with the Samuel Lunenfeld Research Institute of Mount Sinai Hospital to develop stem cell from umbilical cords to treat cardiovascular disease, diabetes and neurological disorders. "With the Toronto area identified as a world-leading cluster in stem cell research, we are extremely excited to have identified this technology as our first commercialisation opportunity," said Dr Hofstein.
  • ts chief executive is Dr Rafi Hofstein. Hofstein has been headhunted from Israel where he was chief executive of Hadasit, the technology transfer company of the Hadassah Medical Organization in Jerusalem and chair of the publicly-traded company Hadasit BioHolding. He brings this considerable experience in technology transfer to what he thinks is a groundbreaking enterprise."MaRS Innovation is a unique global initiative, and I must commend the institutional leaders in Toronto for pulling this innovation powerhouse together to strengthen commercialisation output." He adds: "I believe this is going to modernise the whole notion of tech transfer." He says the scale and diversity of MaRS Innovation's remit puts it into a league of its own. Other research clusters elsewhere in the world have attempted similar projects before, but have been thwarted by the difficulty in bringing parties together. MaRS Innovation will also help launch and grow new spin-off companies and incubate them for 2-3 years to ensure a strong commercial footing. Hofstein says MI will also fund proof of concept trials which will persuade major pharma companies to invest in their development.
  • "Our partnership with MaRS Innovation on developing methods for using stem cells for diseases such as diabetes will allow us to work towards advancing care for these critical conditions."
  • The second collaboration is between MI and The University of Toronto (U of T) and involves a novel sustained release formulation of nitric oxide (NO) for applications in wound healing, including diabetic ulcers. "There are 300 million diabetics worldwide, of which some 15% develop troublesome foot ulcers. This wound healing technology is extremely exciting, making it an early commercialisation opportunity that MaRS Innovation has identified as being a potential win for some 45 million diabetics globally," said Dr Hofstein.
  • "This is one of many new commercialisation ventures that will be initiated by MaRS Innovation, our partner in commercialisation of research with 13 other academic institutions across the Greater Toronto Area," said Paul Young, U of T's vice-president, Research. "We at U of T are delighted that this innovation from Dr Lee will be taken to the marketplace to the benefit of society and the economy of Ontario and Canada." By aggregating the leading edge science of its institutional members and being a one-stop commercialisation centre for industry, entrepreneurs and investors, MI could really help put Toronto and Canada on the map."MaRS Innovation is deeply committed to facilitating strategic research collaborations with industry partners, strengthening the innovation capacity of Canadian industry through adoption of new technologies, and launching a new generation of robust, high-growth Canadian companies that will become global market leaders," added Dr Hofstein. "We look forward to working closely with all of our institutional members and to continue to jointly announce exciting commercial opportunities."
  •  
    Canada has always had to fight hard to attract talent and investment. As stated in Pharmafocus.com, "MaRS Discovery District helps to foster and accelerate the growth of successful Canadian businesses." MaRS Innovation has also been launched to accelerate ideas onto the market.
Assunta Krehl

globeadvisor.com: HOW A GOOD PLAN WENT BAD - 0 views

  • University of Toronto Asset Management
  • Canada's sharpest financial minds
  • runs $2.8-billion of staff pensions and $1.5-billion of endowments, which traditionally produces tens of millions of dollars annually for student aid and faculty posts.
  • ...3 more annotations...
  • But this year the money has stopped flowing after investment losses reached $1.5-billion for 2008 and the university was forced to cancel a planned $62-million endowment payout, representing about 5 per cent of its operating budget.
  • Canada's most innovative investment funds is in question by the university that is bearing the brunt of its losses.
  • Settling into a boardroom chair in the restored heritage building of Toronto's MaRS research centre, Mr. Moriarty remains unshaken by the crisis. He stands committed to UTAM's sophisticated investing approach, reciting phrases like "portable alpha" and "risk budgets" to explain portfolio decisions.
  •  
    University of Toronto remodelled its pension and endowment fund - and then lost $1.5-billion last year. University of Toronto Asset Management runs $2.8-billion of staff pensions and $1.5-billion of endowments, which traditionally produces tens of millions of dollars annually for student aid and faculty posts.runs $2.8-billion of staff pensions and $1.5-billion of endowments, which traditionally produces tens of millions of dollars annually for student aid and faculty posts. Small mention of UTAM at MaRS.
Cathy Bogaart

How Angel Investing Is Different Than Venture Capital - 0 views

  • Ted Wang who has been working on an open source legal project called the Series Seed documents.
  • We have to give a big shout out to Ted: he nailed this. It’s exactly in step with our intention of letting entrepreneurs focus on building businesses in today’s environment, without having to follow old VC rules.
  • Start ups today don’t need to build a manufacturing plant (as DEC, the very first high-tech VC investment, did in 1957) to start a business
  •  
    Ben Horowitz writes in Business Insider's War Room about an open source legal project, Series Seed documents from Ted Wang. He says that these are the kinds of legal docs that the new kind of investor needs to invest in the new kind of company, which generally doesn't require the VC funding structures of the past.
Assunta Krehl

Four Kingston startup companies receive $1.6 million vote of confidence - Innovation Pa... - 2 views

  •  
    Kalgene Diagnostics and Precision Therapeutics receive funding from ParteQ Innovations
  •  
    Four Kingston startup companies receive $1.6 million vote of confidence PARTEQ venture fund's investments help to advance discoveries in pharmaceutical, biomedical and alternative energy sectors. Kalgene, a MaRS client, has received investment from the PARTEQ Venture Fund.
Cathy Bogaart

A Few Examples Of Why Canada Is Creative Central, Village Gamer, Feb 17, 2011 - 0 views

  •  
    The Village Gamer mentions MaRS' funding sources database in a blog that shows how Canada is Creative Central. It's listed along with a number of other awards for those in the digital media space.
Cathy Bogaart

Figuring out financing (PDF) - New & Modern Business, May 2011 - 0 views

  •  
    In this issue of New & Modern Business (PDF) MaRS Advisor Kerri Golden talks about the different types of financing entrepreneurs use to fund their business over the life of the company.
Assunta Krehl

Search Engine Optimization innovators GShift Labs close $1.1 million funding round - Yo... - 0 views

  •  
    gShift Labs, a MaRS client, closed $1.1 million funding round. gSift Labs was named startup of the year in 2010 by the Canadian Innovation Exchanged. gShift Labs is a MaRS Client.
Sarah Hickman

Ministry of Research and Innovation - 0 views

  •  
    MRI maintains the government's commitment to innovation. Its mandate is to: * develop an integrated innovation strategy and guide its delivery * invest in both policies and programs to deliver innovation strategy * foster a culture of innovation & showcase it to world MRI acts as: * listener to advice of experts * matchmaker between innovators and investors * supporter for researchers and innovators (school, culture, business) * promoter of research (lab to marketplace) * pursuer of big ideas (funds) The 4 main branches are: * outreach, promotion, and business development * innovation * research * commercialization
  •  
    MRI maintains the government's commitment to innovation. Its mandate is to: * develop an integrated innovation strategy and guide its delivery * invest in both policies and programs to deliver innovation strategy * foster a culture of innovation & showcase it to world MRI acts as: * listener to advice of experts * matchmaker between innovators and investors * supporter for researchers and innovators (school, culture, business) * promoter of research (lab to marketplace) * pursuer of big ideas (funds) The 4 main branches are: * outreach, promotion, and business development * innovation * research * commercialization
Sarah Hickman

Thomson Financial - Canada's Venture Industry Experts - 0 views

  •  
    A product of Thomson, VCReporter gives access to market intelligence. One can, for example, access profiles of venture-backed companies and analyze trends by sector, geography, and fund manager. VCReporter also provides market news feeds, statistics, free reports and presentations, and a glossary of business terms.
  •  
    A product of Thomson, VCReporter gives access to market intelligence. One can, for example, access profiles of venture-backed companies and analyze trends by sector, geography, and fund manager. VCReporter also provides market news feeds, statistics, free reports and presentations, and a glossary of business terms.
Assunta Krehl

A little venture capital goes a long way - The Globe and Mail - 0 views

  •  
    Omar El Akkad, Globe and Mail Technology Report states "the aftershocks of the global recession have greatly reduced the amount of money big funds are willing to give venture capital firms, and how much money those firms are willing, in turn, to give startups. But with the rise of mobile platforms and Web 2.0, the cost of starting up a tech company today are often much lower than just a few years ago, and venture capital firms are increasingly handing out cash with the expectation that it doesn't take as much money as it used to, to launch the next technology powerhouse." Oct 26, 2009
Assunta Krehl

Toronto-based genomics center gets $5 million injection - Eurelalert - November 1, 2011 - 0 views

  •  
    TCAG, based at The Hospital for Sick Children, located at the MaRS Centre has provided world-leading infrastructure support to over 1,600 labs worldwide. TCAG has received $5 million in funding.
Assunta Krehl

Terry Fox Run is personal now for longtime participant - The Star - September 7, 2012 - 0 views

  •  
    Tom Rand, Managing Partner of the MaRS Cleantech Fund and a Cleantech Advisor, MaRS Discovery District participated in the Terry Fox Foundation fundraising at the MaRS Centre that helped to raise money for the Terry Fox Run that took place September 16.
« First ‹ Previous 41 - 60 of 183 Next › Last »
Showing 20 items per page